Aurinia Announces Results of Annual General Meeting
June 09 2016 - 6:29PM
Business Wire
Aurinia Pharmaceuticals Inc. (“Aurinia” or the
“Company”) (NASDAQ: AUPH / TSX: AUP) is pleased to announce
that the six incumbent directors of the Company were re-elected at
the Company’s annual general meeting held on June 8, 2016 (the
“Meeting”).
Results of the vote by proxy for the election of directors are
provided below:
Nominee
Votes For (%)
Votes Withheld (%)
Election of Directors
Richard Glickman 99.89% 0.11% Charles Rowland Jr. 99.72% 0.28%
Benjamin Rovinski 99.89% 0.11% David Jayne 99.89% 0.11% Gregory
Ayers 99.89% 0.11% Hyuek Joon Lee 99.88% 0.12%
Voting results on all matters voted on at the Meeting will be
filed on SEDAR at www.sedar.com and EDGAR at www.edgar.com.
About Aurinia
Aurinia is a clinical stage pharmaceutical company focused on
the global nephrology market. The fully-enrolled Phase 2b AURA-LV
clinical trial is evaluating the efficacy of its lead drug,
voclosporin, as a treatment for active lupus nephritis (“LN”). LN
is an inflammation of the kidneys, that if inadequately treated can
lead to end-stage renal disease, making LN a serious and
potentially life-threatening condition.
About AURA
The AURA–LV study or “Aurinia Urine Protein Reduction in Active
Lupus Nephritis Study” is an adequate and well-controlled clinical
trial that enrolled 265 patients and is being conducted in over 20
countries worldwide. This trial will compare the efficacy of
voclosporin against placebo in achieving remission in patients with
active lupus nephritis. The AURA-LV study is designed to
demonstrate that voclosporin can induce a rapid and sustained
reduction of proteinuria in the presence of extremely low steroid
exposure. It will compare two dosage groups of voclosporin (23.7mg
and 39.5mg) compared to placebo, with all patients receiving
mycophenolate mofetil (“MMF”) and oral corticosteroids as
background therapy. There will be a primary analysis to determine
complete remission at week 24 (confirmed at 26 weeks) and various
secondary analyses at week 48 which include biomarkers and markers
of non-renal SLE.
We seek Safe Harbor.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160609006522/en/
Aurinia Pharmaceuticals Inc.Michael R. Martin, 250-708-4272Chief
Operating Officermmartin@auriniapharma.comorRenmark Financial
Communications Inc.Barry Mire,
416-644-2020bmire@renmarkfinancial.comorLaura Welsh,
514-939-3989lwelsh@renmarkfinancial.com